CoChat

Pharmacological considerations in the modulation of multidrug resistance

Open access
Fisher, G.A., Lum, B.L., Hausdorff, J., Sikic, B.I. · 1996 · European Journal of Cancer
Cited by 135

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

INTRODUCTION MULTIDRUG RESISTANCE (MDR) is the phenomenoninwhich cancer cells become resistant to an array of chemotherapeutic agents with dissimilar structures and mechanisms of action [ 11. MDR can be mediated by the overexpression of a multidrug transporter, the best studied of which is termed Pglycoprotein (Pgp) [2-61. Pgp is a 170 kd plasma membrane protein with twelve transmembrane domains and two intracellular ATPase sites [7]. Pgp has broad specificity as an energy-dependent efflux pump and effectively transports a variety of amphipathic compounds out of the cell. Substrates for Pgp include many anticancer drugs, most notably those derived from natural products (Table 1). Many intrinsically chemoresistant cancers overexpress Pgp de nova. Other classically chemosensitive malignancies such as breast, ovarian and haematolymphoid cancers seldom express Pgp at diagnosis, yet have a high proportion of cases overexpressing Pgp upon relapse. Several studies have found Pgp expression to be predictive of poor response to chemotherapy and decreased overall survival (see reviews [8-l 01). Expression of Pgp also occurs in certain normal tissues (Table 2). Its presence on the apical surface of cells lining the lumen of large and small bowel, bile canaliculi and proximal renal tubules suggests that it may play a role in the excretion of potentially toxic xenobiotics [l 11. Furthermore, the Pgp expressed along the intraluminal surface of vascular endothelium comprising the blood-brain barrier, placenta and blood-testes barrier may play a role in protecting the CNS (central nervous system), fetus and germinal cells from toxic substances in the circulation [12, 131. Its function in other normal tissues remains a matter of conjecture. The calcium channel blocker, verapamil, was the first noncytotoxic agent found to inhibit the Pgp efflux pump in vitro [ 141. Soon thereafter, numerous other currently approved medications were shown to be modulators of drug resistance in vitro (see Table 3). The potential clinical benefit to be derived from a potent Pgp inhibitor has spawned a new field of drug development and clinical research on the modulation of multidrug resistance (MDR). The purpose of this paper is to review the clinical pharmacology of selected Pgp inhibitors and to assess the impact of normal tissue Pgp inhibition on the disposition and elimination of chemotherapeutic agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/0959-8049(96)00111-6

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 135

Metadata

Authors
Fisher, G. A., Lum, B. L., Hausdorff, J., & Sikic, B. I.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
1996-06
Volume
32
Issue
6
Pages
1082-1088
ISSN
0959-8049 (ISSN-L)
OpenAlex
W1981267478
Cited by
135
References
1
FWCI
5.12
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.